The research, led and funded by AstraZeneca, evaluated reported cases occurring within 14 days of administration of the first or second dose as of April 30, using the Anglo-Swedish drugmaker’s global safety database.
AstraZeneca second dose doesn’t raise risk of rare blood clots: Study
More from Industry NewsMore posts in Industry News »
- Frontline, medical workers need to take booster shots, say experts
- India tells Quad will allow export of 8 mln Indo-Pacific vaccine doses
- We need to be vigilant towards counterfeit products: Nakul Pasricha,President, ASPA
- India tops the chart for approved biosimilars and clinical trials surpassing USA and Europe: 10th Annual Pharma IPR India Conference